All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through a grant from Bristol Myers Squibb and Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
ASCO 2019 | Combination drugs in myeloid disorders
Bookmark this article
Aref Al-Kali from the Mayo Clinic, Rochester, US, speaks with the AML Global Portal (AGP) at ASCO 2019 about combining drugs in myeloid disorders such as acute myeloid leukemia (AML).
Aref Al-Kali stated that he was surprised that less than 10% of the audience at ASCO were combining venetoclax with hypomethylating agents or low dose cytarabine to treat patients with newly diagnosed AML who are unfit for intensive chemotherapy, despite the recent approval in the US. He also highlighted his concerns that some clinicians are using this strategy in the treatment of myelodysplastic syndrome (MDS), for which this combination, particularly venetoclax, has not yet been approved.
Combination drugs in myeloid disorders
More about...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox